DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients

Bady, Pierre; Marosi, Christine; Weller, Michael; Grønberg, Bjørn H; Schultz, Henrik; Taphoorn, Martin J B; Gijtenbeek, Johanna M M; van den Bent, Martin J; von Deimling, Andreas; Stupp, Roger; Malmström, Annika; Hegi, Monika E

doi:10.5167/uzh-218447

Citations

Citation copied

Bady, P., Marosi, C., Weller, M., Grønberg, B. H., Schultz, H., Taphoorn, M. J. B., Gijtenbeek, J. M. M., van den Bent, M. J., von Deimling, A., Stupp, R., Malmström, A., & Hegi, M. E. (2022). DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients. Acta Neuropathologica Communications, 10, 39. https://doi.org/10.1186/s40478-022-01344-5

Abstract

Elderly patients represent a growing proportion of individuals with glioblastoma, who however, are often excluded from clinical trials owing to poor expected prognosis. We aimed at identifying age-related molecular differences that would justify and guide distinct treatment decisions in elderly glioblastoma patients. The combined DNA methylome (450 k) of four IDH wild-type glioblastoma datasets, comprising two clinical trial cohorts, was interrogated for differences based on the patients' age, DNA methylation (DNAm) age acceleration (